Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus.

Détails

Ressource 1Télécharger: BIB_9567E0F4BC9B.P001.pdf (1050.81 [Ko])
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_9567E0F4BC9B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus.
Périodique
Journal of Infectious Diseases
Auteur(s)
Misstear K., McNeela E.A., Murphy A.G., Geoghegan J.A., O'Keeffe K.M., Fox J., Chan K., Heuking S., Collin N., Foster T.J., McLoughlin R.M., Lavelle E.C.
ISSN
1537-6613 (Electronic)
ISSN-L
0022-1899
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
209
Numéro
9
Pages
1479-1484
Langue
anglais
Résumé
Despite showing promise in preclinical models, anti-Staphylococcus aureus vaccines have failed in clinical trials. To date, approaches have focused on neutralizing/opsonizing antibodies; however, vaccines exclusively inducing cellular immunity have not been studied to formally test whether a cellular-only response can protect against infection. We demonstrate that nasal vaccination with targeted nanoparticles loaded with Staphylococcus aureus antigen protects against acute systemic S. aureus infection in the absence of any antigen-specific antibodies. These findings can help inform future developments in staphylococcal vaccine development and studies into the requirements for protective immunity against S. aureus.
Mots-clé
vaccine, Staphylococcus aureus, cellular immunity, mucosal, adjuvant, nanoparticle
Pubmed
Web of science
Open Access
Oui
Création de la notice
13/01/2014 14:57
Dernière modification de la notice
20/08/2019 15:57
Données d'usage